Jean-Loup Romet-Lemonne, MD

Jean-Loup Romet-Lemonne, MD is a prominent figure in the biotechnology industry, serving as the President and Co-Founder of Traverse Biotech, Inc.3 His extensive experience and expertise in the field of immunology and cancer research have positioned him as a key leader in the development of innovative cancer therapies.

Professional Background

Dr. Romet-Lemonne has a distinguished career spanning several decades in the pharmaceutical and biotechnology sectors. Prior to his role at Traverse Biotech, he held significant positions including:

• Senior Advisor at Celdara Medical
• Senior Advisor for Global Development at Institut Pasteur
• Founder and CEO of IDM Pharma, Inc., a NASDAQ-listed company that was later acquired by Takeda Oncology1

Current Role at Traverse Biotech

At Traverse Biotech, Dr. Romet-Lemonne plays a crucial role as the Co-Founder, President, and Principal Investigator.23 The company focuses on late-stage preclinical and early clinical development of immunotherapy products, with a particular emphasis on cancer treatments.

Recent Achievements

Under Dr. Romet-Lemonne's leadership, Traverse Biotech has made significant strides in cancer research:

• The company was recently awarded a Phase I SBIR grant from the National Cancer Institute to develop targeted immunotherapy for selected solid tumors.2
• They are working on a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).2

Expertise and Contributions

Dr. Romet-Lemonne's expertise lies in:

• Immunology and cancer immunotherapy
• Drug development and clinical trials
• Biotechnology entrepreneurship

His contributions to the field are evident in his role as Program Director at the International Union of Immunological Societies (IUIS), an umbrella organization for regional and national immunology societies.6

With over 500 connections on LinkedIn, Dr. Romet-Lemonne maintains an active professional network, sharing insights and updates about advancements in biotech and immunotherapy.45